Explore the vast range of titles available.

Obesity, whose prevalence is pandemic and continuing to increase, is a major preventable and modifiable risk factor for diabetes and cardiovascular diseases, as well as for cancer. Furthermore, epidemiological studies have shown that obesity is a negative independent prognostic factor for several oncological outcomes, including overall and cancer-specific survival, for several site-specific cancers as well as for all cancers combined. Yet, a recently growing body of evidence suggests that sometimes overweight and obesity may associate with better outcomes, and that immunotherapy may show improved response among obese patients compared with patients with a normal weight. The so-called ‘obesity paradox’ has been reported in several advanced cancer as well as in other diseases, albeit the mechanisms behind this unexpected relationship are still not clear. Aim of this review is to explore the expected as well as the paradoxical relationship between obesity and cancer prognosis, with a particular emphasis on the effects of cancer therapies in obese people.

To assess the effect of insulin delivery and glucose monitoring technologies on quality of life in relation with glucose control in adults with type 1 diabetes (T1D). This cross-sectional study included 69 adults with T1D (mean age 39.3 ± 12.1 years; 44.9 % females): 36 on multiple daily insulin injections (MDI) and 33 on continuous subcutaneous insulin infusion (CSII). Patient-reported outcomes were assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), Diabetes-Specific Quality of Life Scale (DSQOLS), and SF-36. Glucose control was evaluated using HbA1c and CGM metrics. Individuals in the CSII group reported higher treatment-related satisfaction (p = 0.004), and better disease acceptance (p = 0.004) compared with individuals on MDI, despite similar age, sex or disease duration (p > 0.34). Time in range (TIR) resulted higher in the CSII group than in the MDI group (p = 0.02), while time below range (TBR) resulted higher in the MDI group compared to CSII (p = 0.03). Individuals reporting high satisfaction scores demonstrated better glucose control metrics compared to those with lower satisfaction levels. The association between satisfaction and TIR was relevant, even after adjusting for treatment modality (p = 0.0003). Technology may improve quality of life over MDI treatment. Improvement in glucose control may partially account for this effect. •Insulin pump (CSII) therapy was associated with higher treatment satisfaction and disease acceptance compared to multiple daily injections (MDI).•Despite the use of diabetes technologies, fear of hypoglycemia and complications remained high and equally distributed among CSII and MDI users.•Patients with higher satisfaction had better glycemic control, suggesting a potential link between perceived well-being and metabolic outcomes.•The study used three validated questionnaires (DTSQ, DSQOLS, SF-36) to comprehensively assess health-related quality of life (HRQoL).•No significant differences in HRQoL were found between different CGM or CSII devices, suggesting comparable performance across technology types.

There is increasing evidence of the role of endocrine disruptors (EDs) derived from commonly employed compounds for manufacturing and processing in altering hormonal signaling and function. Due to their prolonged half-life and persistence, EDs can usually be found not only in industrial products but also in households and in the environment, creating the premises for long-lasting exposure. Polybrominated diphenyl ethers (PBDEs) are common EDs used in industrial products such as flame retardants, and recent studies are increasingly showing that they may interfere with both metabolic and oncogenic pathways. In this article, a multidisciplinary panel of experts of the Italian Association of Medical Diabetologists (AMD), the Italian Society of Diabetology (SID), the Italian Association of Medical Oncology (AIOM), the Italian Society of Endocrinology (SIE) and the Italian Society of Pharmacology (SIF) provides a review on the potential role of PBDEs in human health and disease, exploring both molecular and clinical aspects and focusing on metabolic and oncogenic pathways.